The Oncoprotein HBXIP Activates Transcriptional Coregulatory Protein LMO4 Via Sp1 to Promote Proliferation of Breast Cancer Cells

Overview

Journal Carcinogenesis

Specialty Oncology

Date 2013 Jan 8

PMID 23291272

Citations 34

Authors

Lin Yue

Leilei Li

Fangfang Liu

Nan Hu

Weiying Zhang

Xiao Bai

Yinghui Li

Yingyi Zhang

Li Fu

Xiaodong Zhang

Lihong Ye

Affiliations

Soon will be listed here.

Abstract

Hepatitis B X-interacting protein (HBXIP) is an important oncoprotein that plays critical role in the development of cancer. In this study, we report that HBXIP activates LIM-only protein 4 (LMO4), a transcriptional coregulatory protein, in promotion of cell proliferation. We observed that the messenger RNA (mRNA) expression levels of HBXIP were positively associated with those of LMO4 in clinical breast cancer tissues. We further identified that HBXIP upregulated LMO4 at the levels of promoter, mRNA and protein in MCF-7 and LM-MCF-7 breast cancer cell lines. The expression of cyclin D1 and cyclin E, downstream effectors of LMO4, could be upregulated by HBXIP through LMO4. Then, chromatin immunoprecipitation (ChIP) assay revealed that HBXIP was able to interact with the promoter region of LMO4. Electrophoretic mobility shift assay showed that HBXIP occupied the -237/-206 region of LMO4 promoter containing Sp1 binding element. The mutant of Sp1 binding site in the LMO4 promoter impeded the interaction of HBXIP with the promoter. Co-immunoprecipitation, ChIP and luciferase reporter gene assays showed that HBXIP activated LMO4 promoter through binding to Sp1. In function, flow cytometry, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 5-ethynyl-2'-deoxyuridine (EdU) incorporation assays and animal transplantation assays demonstrated that HBXIP-enhanced cell proliferation of breast cancer through upregulating LMO4 in vitro and in vivo. Thus, we concluded that oncoprotein HBXIP is able to activate the transcriptional coregulatory protein LMO4 through transcription factor Sp1 in promotion of proliferation of breast cancer cells. HBXIP may serve as a driver gene to activate transcription in the development of cancer.

Citing Articles

Oncoprotein LAMTOR5-mediated CHOP silence via DNA hypermethylation and miR-182/miR-769 in promotion of liver cancer growth.

Wang X, Li Q, Tang Y, Li Y, Zhang L, Xu F Acta Pharmacol Sin. 2024; 45(12):2625-2645.

PMID: 38942954 PMC: 11579023. DOI: 10.1038/s41401-024-01310-y.

Prevalence of Hepatitis B Virus Markers among the Women with Breast Cancer.

Fakheri Sueini V, Parsa Nahad M, Talaeizadeh A, Moradi M, Alborzi A, Pirmoradi R Asian Pac J Cancer Prev. 2024; 25(2):547-553.

PMID: 38415541 PMC: 11077112. DOI: 10.31557/APJCP.2024.25.2.547.

HBXIP blocks myosin-IIA assembly by phosphorylating and interacting with NMHC-IIA in breast cancer metastasis.

Zhang L, Zhou X, Liu B, Shi X, Li X, Xu F Acta Pharm Sin B. 2023; 13(3):1053-1070.

PMID: 36970214 PMC: 10031283. DOI: 10.1016/j.apsb.2022.11.025.

KRAS, YWHAE, SP1 and MSRA as biomarkers in endometrial cancer.

Yang Y, Sang Z, Ma J, Zhu Y, Wu S Transl Cancer Res. 2022; 10(3):1295-1312.

PMID: 35116456 PMC: 8797453. DOI: 10.21037/tcr-20-2969.

Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer.

Zhang J, Sun B, Ruan X, Hou X, Zhi J, Meng X Cancer Biol Med. 2021; 18(1):105-119.

PMID: 33628588 PMC: 7877173. DOI: 10.20892/j.issn.2095-3941.2020.0098.

References

Wen Y, Golubkov V, Strongin A, Jiang W, Reed J . Interaction of hepatitis B viral oncoprotein with cellular target HBXIP dysregulates centrosome dynamics and mitotic spindle formation. J Biol Chem. 2007; 283(5):2793-803. DOI: 10.1074/jbc.M708419200. View

Zhang X, Dong N, Yin L, Cai N, Ma H, You J . Hepatitis B virus X protein upregulates survivin expression in hepatoma tissues. J Med Virol. 2005; 77(3):374-81. DOI: 10.1002/jmv.20466. View

Wang F, Sha L, Zhang W, Wu L, Qiao L, Li N . Involvement of hepatitis B X-interacting protein (HBXIP) in proliferation regulation of cells. Acta Pharmacol Sin. 2007; 28(3):431-8. DOI: 10.1111/j.1745-7254.2007.00531.x. View

Wittlin S, Sum E, Jonas N, Lindeman G, Visvader J . Two promoters within the human LMO4 gene contribute to its overexpression in breast cancer cells. Genomics. 2003; 82(3):280-7. DOI: 10.1016/s0888-7543(03)00147-2. View

Sum E, Segara D, Duscio B, Bath M, Field A, Sutherland R . Overexpression of LMO4 induces mammary hyperplasia, promotes cell invasion, and is a predictor of poor outcome in breast cancer. Proc Natl Acad Sci U S A. 2005; 102(21):7659-64. PMC: 1140463. DOI: 10.1073/pnas.0502990102. View

Tian Y, Wang N, Lu Z . Repression of Lim only protein 4-activated transcription inhibits proliferation and induces apoptosis of normal mammary epithelial cells and breast cancer cells. Clin Exp Metastasis. 2010; 27(7):455-63. DOI: 10.1007/s10585-010-9332-1. View

Shan C, Xu F, Zhang S, You J, You X, Qiu L . Hepatitis B virus X protein promotes liver cell proliferation via a positive cascade loop involving arachidonic acid metabolism and p-ERK1/2. Cell Res. 2010; 20(5):563-75. DOI: 10.1038/cr.2010.49. View

Wang Y, Zhang H, Chen Y, Sun Y, Yang F, Yu W . LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell. 2009; 138(4):660-72. DOI: 10.1016/j.cell.2009.05.050. View

Zangemeister-Wittke U, Simon H . An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy. Cell Cycle. 2004; 3(9):1121-3. View

10.

Montanez-Wiscovich M, Shelton M, Seachrist D, Lozada K, Johnson E, Miedler J . Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells. J Pathol. 2010; 222(3):271-81. PMC: 3600378. DOI: 10.1002/path.2762. View

11.

Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, Cornelison R . Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 2002; 62(5):1256-60. View

12.

Liu B, Soloviev I, Huang X, Chang P, Ernst J, Polakis P . Mammary tumor regression elicited by Wnt signaling inhibitor requires IGFBP5. Cancer Res. 2012; 72(6):1568-78. DOI: 10.1158/0008-5472.CAN-11-3668. View

13.

Melegari M, Scaglioni P, Wands J . Cloning and characterization of a novel hepatitis B virus x binding protein that inhibits viral replication. J Virol. 1998; 72(3):1737-43. PMC: 109461. DOI: 10.1128/JVI.72.3.1737-1743.1998. View

14.

Wang W, Zhao L, Tan Y, Ren H, Qi Z . MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma. Carcinogenesis. 2012; 33(5):1113-20. PMC: 3334515. DOI: 10.1093/carcin/bgs113. View

15.

Montanez-Wiscovich M, Seachrist D, Landis M, Visvader J, Andersen B, Keri R . LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression. Oncogene. 2009; 28(41):3608-18. PMC: 2762490. DOI: 10.1038/onc.2009.221. View

16.

Fujii R, Zhu C, Wen Y, Marusawa H, Bailly-Maitre B, Matsuzawa S . HBXIP, cellular target of hepatitis B virus oncoprotein, is a regulator of centrosome dynamics and cytokinesis. Cancer Res. 2006; 66(18):9099-107. DOI: 10.1158/0008-5472.CAN-06-1886. View

17.

Minczuk M, Mroczek S, Pawlak S, Stepien P . Human ATP-dependent RNA/DNA helicase hSuv3p interacts with the cofactor of survivin HBXIP. FEBS J. 2005; 272(19):5008-19. DOI: 10.1111/j.1742-4658.2005.04910.x. View

18.

Dif N, Euthine V, Gonnet E, Laville M, Vidal H, Lefai E . Insulin activates human sterol-regulatory-element-binding protein-1c (SREBP-1c) promoter through SRE motifs. Biochem J. 2006; 400(1):179-88. PMC: 1635455. DOI: 10.1042/BJ20060499. View

19.

Jung J, Arora P, Pagano J, Jang K . Expression of DNA methyltransferase 1 is activated by hepatitis B virus X protein via a regulatory circuit involving the p16INK4a-cyclin D1-CDK 4/6-pRb-E2F1 pathway. Cancer Res. 2007; 67(12):5771-8. DOI: 10.1158/0008-5472.CAN-07-0529. View

20.

Adams R, CARMENA M, Earnshaw W . Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol. 2001; 11(2):49-54. DOI: 10.1016/s0962-8924(00)01880-8. View